Vias Digital’s Post

As the biotech industry continues to attract significant investment, it's crucial to take a critical look at the promises being made. The recent news of Biophta raising 6.5M to transition its eye disease treatments to the clinical stage is undoubtedly attention-grabbing, but it raises an important question: Is this just another case of overhyped biotech? While the promise of a "new standard of care" for eye diseases is certainly enticing, let's not forget the harsh reality of the biotech sector. It's no secret that many companies in this industry have burned through substantial funding without delivering tangible results. The high failure rate of promising treatments in clinical trials is a sobering reminder of the risks involved. The truth is, the biotech landscape is littered with companies that secured millions in funding only to disappoint investors when clinical results didn't meet expectations. This pattern raises concerns about whether the industry is truly focused on genuine innovation or simply churning out inflated promises. It's important for investors and stakeholders to demand more than just hype and headlines. We should be looking for real, tangible progress before celebrating the success of any biotech company. The track record of the industry should serve as a cautionary tale, reminding us to tread carefully when it comes to allocating resources to new ventures. I'm not suggesting that Biophta won't succeed, but it's essential to approach this news with a healthy dose of skepticism. Let's prioritize substance over hope and ensure that any claims of innovation are backed by solid evidence and progress. #Biotech #Innovation #ClinicalTrials #Investment #Skepticism #Healthcare #Biopharmaceuticals #ResearchAndDevelopment #Funding #EyeDiseaseTreatment https://lnkd.in/eXhWbG5i

🚀 Beijing Sets Up 20 Billion Yuan Fund to Boost Life and Health Industry 💡 Are AI powered medical devices eligible for this fund? 🔍 New fund targets innovative drugs and medical devices, eyeing growth in cell therapy and digital healthcare. 🌟 A New Era in Changping In Changping District, the Beijing Pharmaceutical and Health Industry Investment Fund was launched with a robust 20 billion yuan. This fund is a game-changer, targeting breakthroughs in drugs, medical devices, and areas like gene therapy and digital health. 🎯 Towards a Trillion-Yuan Goal Beijing is on a mission to build a trillion-yuan health industry by 2025. This vision reflects the city's commitment to becoming a global leader in healthcare innovation. 💡 Changping: The Heart of Growth The recent forum in Changping marked the fund's kick-off, highlighting the district's significant role in this growth, backed by last year's 91 billion yuan income. With plans to boost over 71 projects, Changping is at the forefront of this health industry evolution. 🌱 A Foundation of Innovation Beijing has been fostering a biopharmaceutical hub since 2000, with the Zhongguancun Life Science Park and over 40,000 companies today. The city's focus on healthcare has led to significant growth and innovation. ✨ Are AI powered medical devices eligible for this fund? The Beijing Pharmaceutical and Health Industry Investment Fund aims to focus on key industrial areas such as innovative drugs and medical devices, as well as emerging fields like cell and gene therapy and digital healthcare. Given this focus, AI-powered medical devices, which can fall under the categories of medical devices and digital healthcare, would likely be eligible for funding from this initiative. 🔍 The Future of Global Health This initiative is just about setting a global standard in healthcare. The combination of strategic investment and innovation positions the city to lead in transforming healthcare worldwide. #HealthcareInnovation #Beijing #DigitalHealth #MedicalDevices #GeneTherapy #Pharmaceuticals #InvestmentInHealth #FutureOfMedicine #innovation #ideation #GlobalImpact

✨ AI is expected to create exceptional growth in the healthcare sector and strives to deliver “healthcare anywhere anytime” as well as addressing the dire labor shortages in healtcare services ✅. The technology is bound to revolutionize medicine and healthcare, addressing such pressing matters as the fight against cancer, autoimmune diseases and many rare illnesses 💥. These are compelling reasons for the AI.FUND to invest in the healthcare sector and has driven one of the latest investment decisions: Mindpeak 🚀. Founded in 2018 by Felix Faber and Dr. Tobias Lang in Hamburg, the startup is the leading provider of AI-powered pathology solutions and has just raised $15.3 million in a Series A funding round💰. This funding round was led by ZEISS Ventures and InnoVentureFund (IFB Innovationsstarter GmbH), with participation from AI.FUND and the European Innovation Council – an amazing lineup of investors and a very promising solution and team 👍🏻 .    Mindpeak's AI algorithms were among the first to be used for routine clinical diagnostics in both the U.S. and the EU💡 . The company's innovative solutions enable automated histological and immunohistochemical tissue analysis and help experts make more confident decisions. To date, more than 30,000 patient diagnoses have been supported using the AI solution. Biopharmaceutical companies also use this AI technology to predict the efficacy of certain cancer drugs and to enable targeted treatments. We are convinced: this AI will save lives based on German AI-technology and innovation 💚 .    While Mindpeak already has a cash-flow positive core business, the new investment will enable the company to further expand the commercialization of its breakthrough technologies across multiple geographies. Also, the funding strengthens the product development roadmap for AI-powered histopathology, supporting clinical laboratories and biopharma companies worldwide 🌎.   Recently, the company has expanded its product portfolio to include pathological analysis of additional organs, biomarkers and stains. Strategic partnerships with leading healthcare organizations such as Roche, as well as positive regulatory developments, further strengthen the company's position in the market. For further information check 👉🏻 https://www.mindpeak.ai   Ragnar Kruse Dr. John Lange Dr. Hauke Hansen Petra Vorsteher Ingo Hoffmann Fabian J. G. Westerheide #artificialintelligence #aination #industrialai #aifuture #aiinhealthcare #aiinnovation #medicaldiagnostics #digitaltransformation #germanpotential #germanytech #investmentopportunities #aiapplications #techleadership #aifund #germaninnovation #techstrategy #digitaleconomy #digitalization #startupecosystem #mindpeak

In a month, two of our Project Leads, Greta Preatoni from MYNERVA and Waldemar Hoffmann from Liver4Life (aka Apersys AG) will head to Boston as part of Venturelab's Venture Leaders Medtech 2024 💫 During the one-week roadshow, the 10 Venture Leaders will meet investors in the USA and engage with executives and experts in the #Medtech industry. Excited to see how this week will transpire 😀 More info about the other Venture Leaders below 👇 #VLeadersMedtech #SwissStartups #MedtechInnovation #InnovationInHealth #SwitzerlandInnovation #FutureOfHealthcare

Last week,I was honnored to participate as #Chair and #Speaker the 15th Global DDF Summit (Drug Delivery & Formulation) Summit, which took place in Berlin. During the summit discussed several topics related to medical devices and drug delivery systems. Here are some key points from the summit: 👉 Bioperformance Prediction: Utilizing data analytics to predict the performance of biologics and drugs in the body. 👉 Prodrug Therapies: Engineering prodrug therapies for infectious diseases and cancer, focusing on targeted delivery and improved efficacy. 👉 Oligonucleotide Lipid Nanoparticles: Advancements in high-throughput screening for gene silencing applications. 👉 Wearable Drug Delivery Systems: Development of high-volume wearable systems for drug delivery. Researchers discussed also how wearable devices and digital solutions can improve medication adherence. 👉 Retinal Drug Delivery: The Port Delivery System with Ranibizumab represents a new paradigm for long-acting retinal drug delivery. 👉 Combination Products: Current challenges and opportunities in developing combination products, including, Human Factors aspects, post-market safety reporting. The experts discussed also how #AI can speed the development and the patient centricity of the drug-Device combination products in the near future. 👉 Biologics and Medical Devices: The evolving relationship between biologics delivery and medical device development. 👉 The summit covered the latest advancements in controlled release technologies: These technologies allow for sustained drug release, reducing the frequency of dosing.Examples include transdermal patches, depot injections, and implantable devices. Overall, the summit provided a platform for experts to exchange ideas, share case studies, and address challenges in drug delivery and formulation. Big thanks to MA Exhibitions for producing such a great event, and to Ahmed Osman and #Team for your dedication and commitment to creating a valuable experience for attendees. #DDFSummit #DrugDelivery #Formulation #DrugDeviceCombinationproducts #AI #DigitalHealthTools #Development

𝗠𝗲𝗺𝗲𝗹 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 & 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗦𝗲𝗿𝘃𝗶𝗰𝗲 Memel Biotech has launched a fully integrated advanced therapy development and manufacturing service from its facility located at the Baltic seaport of Klaipeda, Lithuania.   CEO Agne Vaitkeviciene explains the reasoning behind Memel’s foundation: “Advanced therapies have enormous potential to make life changing impacts on patients, but there is no escaping the fact that they are complex and challenging to manufacture and deliver. Based on our previous experience in the sector, we believe Memel has the portfolio of services and skills to meet the challenges companies that are aiming to make a difference face – from initial formulation to scale-up - whilst conforming to the still emerging regulatory framework. In addition to European clients, our location also offers an ideal EU entry point to US and ROW companies.”   Cureline Group - Global Translational CRO Group President Olga Potapova adds: “Memel is a natural extension of the Group’s portfolio. We have closely followed the development of the advanced therapies sector over the last decade in particular. Rather than try to repurpose any existing CDMO we believe the time is right to create a truly specialized partner who can take an active role in helping customers achieve their missions to bring these exciting new treatments to patients. Lithuania with its highly skilled workforce, supportive environment, stability and EU membership is also an ideal location.” https://lnkd.in/efJQUh44

The Hybrid Drugs that Remepy is developing will transform patient care for many reasons. 1. We will uniquely digitize, scale up and standardize many proven complimentary therapies 2. Will generate consistent real world data that can allow to develop critical digital biomarkers 3. Hybrid drugs are personalized 4. We are using non-invasive interventions to harness the brain to improve drug effects by increasing brain plasticity, triggering the reward system, modulating the immune system and driving behavioral changes. This is made possible because Hybrid drugs combine traditional pharmacological components with non-invasive therapeutic software applications. #precisionmedicine #digitalhealth Or Shoval Amir Amedi Nira Saporta (Rivner) Shahar Shelly M.D Ofer Tur-Sinai Lior Benderski Johnathan Amit Kanarek Sheila Oren, MD MBA Shai Erlich Merav Catalogna, PhD Eran Etam Bar Nathansohn-Levi Dina Kofler Danny Bar-Zohar

Thank you Executive Forecast for the discussion on our contributions to medical innovation and the importance of dialogue among stakeholders in the healthcare ecosystem. These figures actually tell a very powerful story about #Roche: ➡️ 72: New molecular entities in our pipeline tackling diseases like Alzheimer’s, powered by breakthrough technologies such as the brain shuttle. ➡️ #1 in Neurology globally, a leader in Ophthalmology and Oncology/Hematology. ➡️ 18,000 employees: A 127-year legacy in Germany, driving advances in #diagnostics and #pharma. ➡️ 3 billion euros: Investments in Germany over the past five years - a cornerstone of Roche’s global network. ➡️ 2024: A milestone year with #Germany’s Medical Research Law - a first step in revitalizing its clinical trials ecosystem and innovation capacity. As mentioned in my dialogue with Executive Forecast: The work we do today defines the healthcare of tomorrow - or "doing now what patients need next". I very much look forward to 2025 and to strengthening the economic footprint of this key industry sector with all my colleagues and our #partners in Germany. 👉 https://lnkd.in/egas7kGh

Qure.ai, a New York City-based company specializing in AI-augmented detection for Tuberculosis (TB), Lung Cancer, and Stroke, has received an investment from Merck Global Health Innovation Fund for its Series D funding round. While the amount of the investment was not disclosed, Qure.ai plans to use this capital further to develop foundation models for AI in medical imaging and expand the geographical reach of its AI-powered imaging solutions, particularly into the U.S. market. This investment from a major pharmaceutical company's innovation fund highlights the growing importance of AI in medical diagnostics and Qure.ai's potential to make significant advancements in this field. https://lnkd.in/gaxt7DVq